The EpiVax Team
Rich-Henry Schabowsky, PhD JD
CEO
Rich-Henry Schabowsky, PhD, JD, has recently joined EpiVax leadership as Chief Executive Officer. His extensive experience and diverse skill set make him an outstanding choice for the CEO position, promising to drive innovation and growth.
Rich-Henry holds a bachelor’s degree in economics, a master’s and Ph.D. in Microbiology and Immunology, as well as a J.D. Starting his career as a researcher in vaccine development, he later became a partner and registered patent attorney at Dinsmore & Shohl LLP, specializing in IP protection for life science, biotech, and tech companies.
Joining EpiVax in 2021 as the Scientific and Intellectual Property Director, he spearheaded the company’s IP strategy for protecting immunoinformatics tools and therapeutics developed therefrom. More recently, he took on the role of partner at Thursday Ventures, a venture firm investing in early-stage frontier technology. He also recently served as CEO of Thursday’s talent acquisition firm, Towerhill Associates, and currently sits on the board of Biobot Analytics. Rich-Henry’s multidisciplinary background uniquely positions him at the intersection of science, law, and operations.
Beyond his corporate endeavors, Rich-Henry is actively involved in community service, serving on the board of Clínica Esperanza/Hope Clinic and teaching Brazilian jiu-jitsu to youth in his local community.
Anne (Annie) S. De Groot, M.D.
FOUNDER & CSO
Anne De Groot is internationally known for her research on the human immune system’s response to vaccines and therapeutics. She graduated from Smith College in 1978 and earned her medical degree at University of Chicago in 1983. After internal medical residency, she obtained advanced training in immunoinformatics and vaccinology with Michael Good, Russell Howard and Jay Berzofsky at the National Institutes of Health, and then returned for a fellowship in ID at New England Medical Center.
ORCID https://orcid.org/0000-0001-5911-1459
Read More
William Martin
FOUNDER, CIO & CTO
William Martin is the principal architect and developer of the EpiMatrix System. Building on the work done in Dr. De Groot’s Brown University laboratory, Mr. Martin has revised and expanded the EpiMatrix toolkit. In addition to developing new and improved predictive matrices for many Class I and Class II HLA alleles, Mr. Martin has developed a suite of protocols, ancillary tools and database structures allowing for fast and efficient analysis of input protein sequences.
Brad Crevier, JD
CFO
Brad Crevier, JD, is responsible for managing all strategic financial objectives at EpiVax, providing crucial financial information and operational analytics to the executive team. He has a wealth of financial management experience, most recently as Assistant Treasurer at audio technology company Sonos, where he also held the positions of Director of Treasury and Director of International Tax, contributing to the company’s successful IPO. Additionally, Brad has previous experience at PE-backed The Rockport Group and the Boston offices of Deloitte and PwC. He is a bar-certified attorney with a JD and MSA/MBA from Northeastern University.
As a senior global finance executive, Brad brings deep expertise in corporate and capital structuring, finance policy implementation, treasury operations, tax strategy, and risk management across diverse business landscapes.
Amy Rosenberg, M.D.
SENIOR DIRECTOR OF IMMUNOLOGY AND PROTEIN THERAPEUTICS
Amy Rosenberg is a physician immunologist with extensive expertise in development and immunogenicity of therapeutic protein and cellular products. During her 30+ years at the FDA, Amy was principal or intimately involved in the regulation and approval of numerous FDA regulated products. Amy joined EpiVax in September 2021 as Senior Director of Immunology and Protein Therapeutics.
Read More
Aimee Mattei, MS
DIRECTOR OF BIOINFORMATICS
Aimee manages a team of analysts and project managers providing in silico immunogenicity risk assessments supporting research, collaborative, and commercial projects.
She leads the development of novel in silico methods and tools for assessing immunogenic risk of peptide impurities, including sequences containing unnatural amino acids. She holds an M.S. in Pharmaceutical Chemistry and has previous experience in the design, synthesis, purification, and characterization of peptides supporting research programs from concept assessment through lead optimization in the endocrinology and oncology therapeutic areas.
Matthew Ardito
DIRECTOR OF IT
In his early years at EpiVax, Matthew Ardito assisted in maintaining applications associated with the design and reengineering of protein therapeutics and antibody structures, as well as genome mining, epitope mapping, and vaccine design. In 2016, Matt was promoted to Principal Applications Developer and Codebase Manager, where he led a team of developers in the design, development, implementation, testing, and deployment of immunoinformatics applications. In 2021, Matt was promoted again to Director of IT, where he is responsible for the management, strategy, and execution related to the maintenance of IT infrastructure at EpiVax.
Read More
Brian J. Roberts, Ph.D.
SCIENTIFIC DIRECTOR, PRECLINICAL IMMUNOLOGY
Brian Roberts is the scientific director of the Preclinical Immunology program. Dr. Roberts received his PhD in Cell and Molecular Biology from the University of Vermont in 2012. His research in the laboratory of Dr Sally Huber focused on the role of toll-like receptors in sex differences in viral-induced autoimmune myocarditis. Dr. Roberts joined EpiVax in 2015 as a postdoctoral researcher working primarily with the Tregitope team. In 2018 he became manager of the Protein Therapeutics group at EpiVax, and oversees the PANDA projects.